Zaoutis Theoklis E, Heydon Kateri, Localio Russell, Walsh Thomas J, Feudtner Chris
Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Clin Infect Dis. 2007 May 1;44(9):1187-93. doi: 10.1086/513196. Epub 2007 Mar 19.
The incidence of candidiasis has increased in neonatal intensive care units, and invasive candidiasis is associated with significant morbidity and mortality. However, few data exist on outcomes directly attributable to neonatal candidiasis.
We estimated the incidence of systemic candidiasis in hospitalized neonates within the United States and determined the attributable mortality, length of hospital stay, and associated costs. We used the 2003 Kid's Inpatient Database from the Healthcare Cost and Utilization Project. Systemic candidiasis and comorbidities were defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Neonates with uncomplicated births and neonates who died within the first 3 days of life were excluded. We used propensity score methods to balance covariates between the neonates with and neonates without candidiasis. Attributable outcomes were calculated between propensity score-matched neonates with and neonates without candidiasis. Because of the known confounding effect of birth weight, we performed separate propensity score analyses for extremely low birth weight (ELBW) neonates (i.e., neonates weighing < 1000 g).
The overall incidence of invasive candidiasis in neonates is 15 cases per 10,000 neonatal admissions (95% confidence interval [CI], 13-16 cases per 10,000 neonatal admissions). ELBW neonates with invasive candidiasis were 2 times more likely to die (odds ratio, 2.2; 95% CI, 1.4-3.5) than propensity-matched ELBW neonates without candidiasis. The propensity score-adjusted mortality rate attributable to candidiasis among ELBW neonates was 11.9%. Candidiasis in ELBW infants was not associated with an increase in length of hospital stay but was associated with a mean increase in total charges of $39,045 (95% CI, $1374-$76,715). Among infants with a birth weight > or = 1000 g, those who had candidiasis did not experience a significant increase in mortality, compared with infants without candidiasis. However, the propensity score-adjusted length of stay and charges attributable to candidiasis among neonates with a birth weight > or = 1000 g were 16 days (95% CI, 8-24 days) and $122,302 (95% CI, $80,457-$164,148), respectively.
Invasive candidiasis is associated with a significantly increased risk of death and excess hospital charges in ELBW neonates and with excess hospital stay and excess hospital charges in neonates with a birth weight > or = 1000 g.
念珠菌病在新生儿重症监护病房的发病率有所上升,侵袭性念珠菌病与显著的发病率和死亡率相关。然而,关于新生儿念珠菌病直接导致的后果的数据很少。
我们估计了美国住院新生儿系统性念珠菌病的发病率,并确定了可归因的死亡率、住院时间和相关费用。我们使用了医疗成本和利用项目2003年的儿童住院数据库。系统性念珠菌病和合并症通过国际疾病分类第九版临床修订本编码进行定义。排除出生时无并发症的新生儿和出生后3天内死亡的新生儿。我们使用倾向评分方法来平衡有念珠菌病和无念珠菌病新生儿之间的协变量。在倾向评分匹配的有念珠菌病和无念珠菌病的新生儿之间计算可归因的结局。由于出生体重已知的混杂效应,我们对极低出生体重(ELBW)新生儿(即体重<1000 g的新生儿)进行了单独的倾向评分分析。
新生儿侵袭性念珠菌病的总体发病率为每10000例新生儿入院15例(95%置信区间[CI],每10000例新生儿入院13 - 16例)。患有侵袭性念珠菌病的ELBW新生儿死亡的可能性是倾向评分匹配的无念珠菌病的ELBW新生儿的2倍(优势比,2.2;95% CI,1.4 - 3.5)。ELBW新生儿中念珠菌病可归因的倾向评分调整死亡率为11.9%。ELBW婴儿的念珠菌病与住院时间增加无关,但与总费用平均增加39045美元相关(95% CI,1374 - 76715美元)。在出生体重≥1000 g的婴儿中,与无念珠菌病的婴儿相比,患有念珠菌病的婴儿死亡率没有显著增加。然而,出生体重≥1000 g的新生儿中念珠菌病可归因的倾向评分调整住院时间和费用分别为16天(95% CI,8 - 24天)和122302美元(95% CI,80457 - 164148美元)。
侵袭性念珠菌病与ELBW新生儿死亡风险显著增加和医院费用过高相关,与出生体重≥1000 g的新生儿住院时间过长和医院费用过高相关。